1-5 of 5
Ana Marin Niebla, PhD
Close
Sort by
Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Francine M. Foss, MD, Won-Seog Kim, MD PhD, Eric Jacobsen, MD, Maria de Fatima De La Cruz, MD, Dolores Caballero, MD PhD, Ranjana H Advani, MD, Jose Maria Roncero, MD, Raquel de Oña, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, Maria Jose Terol, Eva Domingo-Domenech, MD, Miguel A. Piris, Marta Rodriguez, James Bolognese, PhD, Linda Kessler, BA, Vishnu Mishra, PhD, Robert Curry, BA, MBA, Michael Kurman, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 468.
https://doi.org/10.1182/blood-2019-128513
Published: 2019
Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Juan-Manuel Sancho, MD PhD, Olga García, Pablo Mozas, Santiago Mercadal, MD, Eva Donato, MD, Ana Muntañola Prat, MD, Javier Lopez Jimenez, MD, Pascual Fernandez Abellan, PhD, Jose-Angel Hernandez, MD, Maria J. Rodriguez-Salazar, MD, Samuel Romero, MD, Ana Marin Niebla, PhD, Angel Ramirez Payer, Raul Cordoba, MD PhD, Jose Luis Bello, MD, Beatriz Cuevas, MD, Itziar Oiartzabal, MD, Alejandro Martín, MD PhD, Jose Javier Sanchez Blanco, Nicholas Kelleher, MD, Ana Lafuente, MD, Marc Sorigué, MD, López Guillermo Armando, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5249.
https://doi.org/10.1182/blood-2019-125921
Published: 2019
Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Eva Gine, MD, Maria de Fatima De La Cruz, MD, Carlos Grande, MD, Javier Lopez Jimenez, MD PhD, Alejandro Martín, MD PhD, Maria Jose Terol, Eva González-Barca, MD PhD, Adolfo de la Fuente, Ana Marin Niebla, PhD, Maria Casanova, MD, Ana Muntañola Prat, MD, Tomás José González-López, MD, Marta Aymerich, Lucia Palacios, MSC, Xavier Setoain, Montserrat Cortés-Romera, MD, Amanda Rotger, MD, Alejandro Medina, MD, Ramón García-Sanz, MD PhD, Elias Campo, Armando Lopez-Guillermo
Journal: Blood
Blood (2019) 134 (Supplement_1): 752.
https://doi.org/10.1182/blood-2019-122191
Published: 2019
Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2937.
https://doi.org/10.1182/blood-2018-99-116277
Published: 2018
Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Eva González-Barca, MD PhD, Alejandro Martín, MD, Jose Luis Bello, Juan Miguel Miguel Bergua Burgues, Carlos Panizo, MDPhD, Maite Encuentra, Ana Monter Rovira, Raul Cordoba, MD PhD, Mariana Bastos, MD, Jose Javier Sanchez Blanco, Pilar Gomez, Ana Marin Niebla, PhD, Sonia González de Villambrosia, MD, Maria Jose Sayas, Hugo Daniel Luzardo Henriquez, MD, Maria De La Cruz Viguria Alegria, Blanca Sanchez-Gonzalez, MD PhD, Monica Roig, Jaime Perez De Oteyza, MDPhD, Elena Cabezudo, Lourdes Escoda, MD, Raquel de Oña, Josë Antonio Queizan, Maria Stefania Infante, Ana Muntañola Prat, Andres Lopez
Journal: Blood
Blood (2018) 132 (Supplement 1): 1637.
https://doi.org/10.1182/blood-2018-99-110792
Published: 2018